Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 126

1.

Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials.

Combe B, Behrens F, McHugh N, Brock F, Kerkmann U, Kola B, Gallo G.

J Rheumatol. 2016 May 1. pii: jrheum.151290. [Epub ahead of print]

PMID:
27134249
2.

Association analysis of psoriasis vulgaris and psoriatic arthritis with loss-of-function mutations in IL36RN in German patients.

Löhr S, Uebe S, Behrens F, Böhm B, Köhm M, Traupe H, Oji V, Burkhardt H, Reis A, Hüffmeier U.

Br J Dermatol. 2016 Apr 1. doi: 10.1111/bjd.14624. [Epub ahead of print]

PMID:
27038307
3.

Replication of a distinct psoriatic arthritis risk variant at the IL23R locus.

Budu-Aggrey A, Bowes J, Loehr S, Uebe S, Zervou MI, Helliwell P, Ryan AW, Kane D, Korendowych E, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Behrens F, Burkhardt H, Huffmeier U, Ho P, Martin J, Castañeda S, Goulielmos G, Reis A, Barton A.

Ann Rheum Dis. 2016 Mar 25. pii: annrheumdis-2016-209290. doi: 10.1136/annrheumdis-2016-209290. [Epub ahead of print] No abstract available.

4.

Association of Improvement in Pain with Therapeutic Response as Determined by Individual Improvement Criteria in Patients with Rheumatoid Arthritis.

Scharbatke EC, Behrens F, Schmalzing M, Koehm M, Greger G, Gnann H, Burkhardt H, Tony HP.

Arthritis Care Res (Hoboken). 2016 Mar 18. doi: 10.1002/acr.22884. [Epub ahead of print]

PMID:
26990995
5.

An Individual's Rate of Forgetting Is Stable Over Time but Differs Across Materials.

Sense F, Behrens F, Meijer RR, van Rijn H.

Top Cogn Sci. 2016 Jan;8(1):305-21. doi: 10.1111/tops.12183. Epub 2016 Jan 8.

PMID:
26748838
6.

[Do we still need clinical studies in rheumatology?].

Henkemeier U, Alten R, Bannert B, Baraliakos X, Behrens F, Heldmann F, Kiltz U, Köhm M, König R, Leipe J, Müller-Ladner U, Rech J, Riechers E, Rubbert-Roth A, Schmidt RE, Schulze-Koops H, Specker C, Tausche AK, Wassenberg S, Witt M, Witte T, Zernicke J, Burkhardt H.

Z Rheumatol. 2016 Feb;75(1):4-10. doi: 10.1007/s00393-015-1687-x. German.

PMID:
26680367
7.

Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.

Behrens F, Koehm M, Arndt U, Wittig BM, Greger G, Thaçi D, Scharbatke E, Tony HP, Burkhardt H.

J Rheumatol. 2016 Mar;43(3):632-9. doi: 10.3899/jrheum.141596. Epub 2015 Dec 15.

8.

Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis.

Köhm M, Burkhardt H, Behrens F.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S109-14. Epub 2015 Oct 15. Review.

PMID:
26472504
9.

Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.

Bowes J, Budu-Aggrey A, Huffmeier U, Uebe S, Steel K, Hebert HL, Wallace C, Massey J, Bruce IN, Bluett J, Feletar M, Morgan AW, Marzo-Ortega H, Donohoe G, Morris DW, Helliwell P, Ryan AW, Kane D, Warren RB, Korendowych E, Alenius GM, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Brown MA, Ho P, Behrens F, Burkhardt H, Reis A, Barton A.

Nat Commun. 2015 Jul 6;6:7741. doi: 10.1038/ncomms8741. No abstract available.

PMID:
26145464
10.

[Pharmacotherapy of psoriatic arthritis. Treatment recommendations against the background of limited evidence].

Köhm M, Behrens F.

Z Rheumatol. 2015 Jun;74(5):398-405. doi: 10.1007/s00393-014-1530-9. German.

PMID:
26085072
11.

PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus.

Bowes J, Loehr S, Budu-Aggrey A, Uebe S, Bruce IN, Feletar M, Marzo-Ortega H, Helliwell P, Ryan AW, Kane D, Korendowych E, Alenius GM, Giardina E, Packham J, McManus R, FitzGerald O, Brown MA, Behrens F, Burkhardt H, McHugh N, Huffmeier U, Ho P, Reis A, Barton A.

Ann Rheum Dis. 2015 Oct;74(10):1882-5. doi: 10.1136/annrheumdis-2014-207187. Epub 2015 Apr 28.

12.

The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.

Feuchtenberger M, Kleinert S, Scharbatke EC, Gnann H, Behrens F, Wittig BM, Greger G, Tony HP.

Clin Exp Rheumatol. 2015 May-Jun;33(3):321-9. Epub 2015 Apr 14.

PMID:
25897681
13.

Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.

Bowes J, Budu-Aggrey A, Huffmeier U, Uebe S, Steel K, Hebert HL, Wallace C, Massey J, Bruce IN, Bluett J, Feletar M, Morgan AW, Marzo-Ortega H, Donohoe G, Morris DW, Helliwell P, Ryan AW, Kane D, Warren RB, Korendowych E, Alenius GM, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Brown MA, Ho P, Behrens F, Burkhardt H, Reis A, Barton A.

Nat Commun. 2015 Feb 5;6:6046. doi: 10.1038/ncomms7046. Erratum in: Nat Commun. 2015;6:7741.

14.

Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study.

Thaçi D, Behrens F, Greger G, Burkhardt H, Gnann H, Schopf R, Wittig BM.

Dermatology. 2015;230(3):213-21. doi: 10.1159/000371546. Epub 2015 Jan 27.

PMID:
25632852
15.

Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature.

Behrens F, Cañete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B.

Rheumatology (Oxford). 2015 May;54(5):915-26. doi: 10.1093/rheumatology/keu415. Epub 2014 Oct 27. Review.

PMID:
25349441
16.

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, Korkosz M, Rekalov D, Zupanets IA, Ejbjerg BJ, Geiseler J, Fresenius J, Korolkiewicz RP, Schottelius AJ, Burkhardt H.

Ann Rheum Dis. 2015 Jun;74(6):1058-64. doi: 10.1136/annrheumdis-2013-204816. Epub 2014 Feb 17.

17.

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D.

J Am Acad Dermatol. 2013 Nov;69(5):729-35. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.

PMID:
23981683
18.

Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not?

Gramsch C, Göricke SL, Behrens F, Zimmer L, Schadendorf D, Krasny A, Forsting M, Schlamann MU.

Eur Radiol. 2013 Sep;23(9):2622-7. doi: 10.1007/s00330-013-2857-3. Epub 2013 May 14.

PMID:
23670820
19.

Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis.

Behrens F, Tony HP, Alten R, Kleinert S, Scharbatke EC, Köhm M, Gnann H, Tams J, Greger G, Burkhardt H.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1608-16. doi: 10.1002/acr.22037.

20.

Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis.

Apel M, Uebe S, Bowes J, Giardina E, Korendowych E, Juneblad K, Pasutto F, Ekici AB, McManus R, Ho P, Bruce IN, Ryan AW, Behrens F, Böhm B, Traupe H, Lohmann J, Gieger C, Wichmann HE, Padyukov L, Fitzgerald O, Alenius GM, McHugh NJ, Novelli G, Burkhardt H, Barton A, Reis A, Hüffmeier U.

Arthritis Rheum. 2013 May;65(5):1224-31. doi: 10.1002/art.37885.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk